Skip to main content
Premium Trial:

Request an Annual Quote

Hangzhou Clongene Biotech, Gold Colloid Sign US Distribution Deal for Rapid Tests

NEW YORK – Rapid test maker Hangzhou Clongene Biotech and diagnostics product distributor Gold Colloid on Friday said they inked a deal to distribute Clongene's in vitro­ diagnostics products in the US.

La Mesa, California-based Gold Colloid will distribute Hangzhou, China-based Clongene's point-of-care and home-use rapid tests for drugs of abuse, fertility, and pregnancy, among other tests, as well as materials sold by Clongene for use in the production of IVD tests.

Financial and other terms of the deal were not disclosed.

"Clongene's commitment to quality and innovation aligns perfectly with our values, and we believe their products will play a vital role in improving healthcare access and outcomes across the country," Gold Colloid CEO Daniel Levenson said in a statement.

The firms said the collaboration will provide faster and more convenient testing options that could improve patient care and public health outcomes.